Flavia De Bernardis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Flavia De Bernardis has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Antonio Cassone
Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy
2 shared publications- Francesca Mondello
Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
2 shared publications Adriana Cataldo
Department of Infectious Diseases, Catholic University, Rome, Italy
1 shared publication- Antonietta Girolamo
Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
1 shared publication - Antonio Cassone
Center of Genomic, Genetic and Biology, 53100 Siena, Italy
1 shared publication Consuelo Amantini
Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino
1 shared publication
Latest Publications
- Open Access
- 3 November 2006
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 6 (1) , 158
In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species
Recent investigations on the antifungal properties of essential oil of Melaleuca alternifolia Cheel (Tea Tree Oil, TTO) have been performed with reference to the treatment of vaginal candidiasis. However, there is a lack of in vivo data supporting in vitro results, especially regarding the antifungal properties of TTO constituents. Thus, the aim of our study was to investigate the in vitro and the in vivo anti-Candida activity of two critical bioactive constituents of TTO, terpinen-4-ol and 1,8-cineole. Oophorectomized, pseudoestrus rats under estrogen treatment were used for experimental vaginal infection with azole (fluconazole, itraconazole) -susceptible or -resistant strains of C. albicans. All these strains were preliminarily tested for in vitro susceptibility to TTO, terpinen-4-ol and 1,8-cineole for their antifungal properties, using a modification of the CLSI (formerly NCCLS) reference M27-A2 broth micro-dilution method. In vitro minimal inhibitory concentrations (MIC90) values were 0.06% (volume/volume) for terpinen-4-ol and 4% (volume/volume) for 1,8-cineole, regardless of susceptibility or resistance of the strains to fluconazole and itraconazole. Fungicidal concentrations of terpinen-4-ol were equivalent to the candidastatic activity. In the rat vaginal infection model, terpinen-4-ol was as active as TTO in accelerating clearance from the vagina of all Candida strains examined. Our data suggest that terpinen-4-ol is a likely mediator of the in vitro and in vivo activity of TTO. This is the first in vivo demonstration that terpinen-4-ol could control C. albicans vaginal infections. The purified compound holds promise for the treatment of vaginal candidiasis, and particularly the azole-resistant forms.
- 3 November 2006
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 6 (1) , 158
Open AccessIn vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species
Recent investigations on the antifungal properties of essential oil of Melaleuca alternifolia Cheel (Tea Tree Oil, TTO) have been performed with reference to the treatment of vaginal candidiasis. However, there is a lack of in vivo data supporting in vitro results, especially regarding the antifungal properties of TTO constituents. Thus, the aim of our study was to investigate the in vitro and the in vivo anti-Candida activity of two critical bioactive constituents of TTO, terpinen-4-ol and 1,8-cineole. Oophorectomized, pseudoestrus rats under estrogen treatment were used for experimental vaginal infection with azole (fluconazole, itraconazole) -susceptible or -resistant strains of C. albicans. All these strains were preliminarily tested for in vitro susceptibility to TTO, terpinen-4-ol and 1,8-cineole for their antifungal properties, using a modification of the CLSI (formerly NCCLS) reference M27-A2 broth micro-dilution method. In vitro minimal inhibitory concentrations (MIC90) values were 0.06% (volume/volume) for terpinen-4-ol and 4% (volume/volume) for 1,8-cineole, regardless of susceptibility or resistance of the strains to fluconazole and itraconazole. Fungicidal concentrations of terpinen-4-ol were equivalent to the candidastatic activity. In the rat vaginal infection model, terpinen-4-ol was as active as TTO in accelerating clearance from the vagina of all Candida strains examined. Our data suggest that terpinen-4-ol is a likely mediator of the in vitro and in vivo activity of TTO. This is the first in vivo demonstration that terpinen-4-ol could control C. albicans vaginal infections. The purified compound holds promise for the treatment of vaginal candidiasis, and particularly the azole-resistant forms.
- Open Access
- 1 May 2004
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 41 (1) , 27-34
Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo byCandida albicanswithout selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility
Highly active anti-retroviral therapies (HAART) with human immunodeficiency virus (HIV) protease inhibitors (PIs) or nonnucleoside reverse-transcript
- 1 May 2004
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 41 (1) , 27-34
Open AccessAnti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo byCandida albicanswithout selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility
Highly active anti-retroviral therapies (HAART) with human immunodeficiency virus (HIV) protease inhibitors (PIs) or nonnucleoside reverse-transcript
- Open Access
- 1 September 2002
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (9) , 4791-4797
Immune Cell-Mediated Protection against Vaginal Candidiasis: Evidence for a Major Role of Vaginal CD4+T Cells and Possible Participation of Other Local Lymphocyte Effectors
The protective roles of different lymphocyte subsets were investigated in a rat vaginal candidiasis model by adoptive transfer of vaginal lymphocytes (VL) or sorted, purified CD3+T cells, CD4+or CD8+T cells, or CD3−CD5+B cells from the vaginas of naïve or immune rats following three rounds ofCandida albicansinfection. The adoptive transfer of total VL from nonimmune animals did not alter the course of vaginal candidiasis of the recipient rats. In contrast, the animals receiving total VL or CD3+T cells from immune rats showed a highly significant acceleration of fungus clearance compared with animals which received nonimmune VL. The animals with vaginal CD3−CD5+B cells transferred from immune rats also had fewerCandidaCFU than the controls, but fungal clearance was significantly retarded with respect to the animals administered immune T cells. Sorted, purified CD4+and CD8+vaginal T cells from immune rats were also adoptively transferred to naïve animals. Although both populations were seen to accelerate the clearance of the fungus from the vagina, CD4+T cells were much more effective than CD8+T cells. Overall, there was no difference between the antifungal effects of immune vaginal CD4+T cells and those achievable with the transfer of whole, immune VL. Histological observations of the vaginal tissues of rats with adoptively transferred immune T cells demonstrated a remarkable accumulation of lymphocytes in the subepithelial lamina propria and also infiltrating the mucosal epithelium. These results strongly suggest that distinct vaginal lymphocyte subsets participate in the adaptive anti-Candidaimmunity at the vaginal level, with the vaginal CD4+T cells probably playing a major role.
- 1 September 2002
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (9) , 4791-4797
Open AccessImmune Cell-Mediated Protection against Vaginal Candidiasis: Evidence for a Major Role of Vaginal CD4+T Cells and Possible Participation of Other Local Lymphocyte Effectors
The protective roles of different lymphocyte subsets were investigated in a rat vaginal candidiasis model by adoptive transfer of vaginal lymphocytes (VL) or sorted, purified CD3+T cells, CD4+or CD8+T cells, or CD3−CD5+B cells from the vaginas of naïve or immune rats following three rounds ofCandida albicansinfection. The adoptive transfer of total VL from nonimmune animals did not alter the course of vaginal candidiasis of the recipient rats. In contrast, the animals receiving total VL or CD3+T cells from immune rats showed a highly significant acceleration of fungus clearance compared with animals which received nonimmune VL. The animals with vaginal CD3−CD5+B cells transferred from immune rats also had fewerCandidaCFU than the controls, but fungal clearance was significantly retarded with respect to the animals administered immune T cells. Sorted, purified CD4+and CD8+vaginal T cells from immune rats were also adoptively transferred to naïve animals. Although both populations were seen to accelerate the clearance of the fungus from the vagina, CD4+T cells were much more effective than CD8+T cells. Overall, there was no difference between the antifungal effects of immune vaginal CD4+T cells and those achievable with the transfer of whole, immune VL. Histological observations of the vaginal tissues of rats with adoptively transferred immune T cells demonstrated a remarkable accumulation of lymphocytes in the subepithelial lamina propria and also infiltrating the mucosal epithelium. These results strongly suggest that distinct vaginal lymphocyte subsets participate in the adaptive anti-Candidaimmunity at the vaginal level, with the vaginal CD4+T cells probably playing a major role.